PIK3CA and neoplasm: In PDAC, activation of the oncogenic PI3K/AKT/mTOR signalling is linked to increased tumour growth, drug resistance and epithelial‐mesenchymal transition, weakened apoptosis and tumour immunogenicity, and worse pathological and clinical outcomes.44, 45, 46, 47, 48